Therapeutic Area | MeSH |
---|---|
nervous system diseases | D009422 |
immune system diseases | D007154 |
Tradename | Proper name | Company | Number | Date | Products |
---|---|---|---|---|---|
Avonex | interferon beta-1a | Biogen | N-103628 RX | 2003-05-28 | 2 products |
Rebif | interferon beta-1a | EMD Serono | N-103780 RX | 2002-03-07 | 6 products |
Brand Name | Status | Last Update |
---|---|---|
avonex | Biologic Licensing Application | 2016-03-31 |
avonex avonex avonex pen | Biologic Licensing Application | 2020-12-16 |
avonex avonex pen | Biologic Licensing Application | 2024-11-13 |
rebif | Biologic Licensing Application | 2010-01-14 |
rebif rebif rebidose | Biologic Licensing Application | 2025-09-22 |
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
multiple sclerosis | EFO_0003885 | D009103 | G35 |
Expiration | Code | ||
---|---|---|---|
interferon beta-1a, Avonex, Biogen Inc. | |||
2103-05-17 | Orphan excl. |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Multiple sclerosis | D009103 | EFO_0003885 | G35 | 8 | 23 | 31 | 28 | 64 | 152 |
Relapsing-remitting multiple sclerosis | D020529 | EFO_0003929 | — | 4 | 15 | 31 | 29 | 29 | 107 |
Sclerosis | D012598 | — | — | 1 | 8 | 6 | 15 | 19 | 48 |
Covid-19 | D000086382 | — | U07.1 | — | 4 | 7 | 2 | 3 | 15 |
Injection site reaction | D000075662 | — | — | — | — | — | 1 | 1 | 2 |
Optic neuritis | D009902 | EFO_0007405 | H46 | — | — | — | 2 | — | 2 |
Erythema | D004890 | — | L53.9 | — | — | — | 1 | — | 1 |
Transverse myelitis | D009188 | — | G37.3 | — | — | — | 1 | — | 1 |
Cerebellar diseases | D002526 | — | — | — | — | — | 1 | — | 1 |
Neuritis | D009443 | — | — | — | — | — | 1 | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Recurrence | D012008 | — | — | — | 2 | 3 | — | 2 | 7 |
Coronavirus infections | D018352 | EFO_0007224 | B34.2 | — | 1 | 3 | — | 1 | 4 |
Respiratory distress syndrome | D012128 | EFO_1000637 | J80 | — | — | 1 | — | 1 | 2 |
Coronavirus | D017934 | — | — | — | 1 | 1 | — | 1 | 2 |
Autoimmune diseases | D001327 | EFO_0000540 | M30-M36 | — | 1 | 1 | — | — | 2 |
Sars-cov-2 | D000086402 | — | — | — | 1 | 1 | — | — | 2 |
Severe acute respiratory syndrome | D045169 | EFO_0000694 | J12.81 | — | — | 2 | — | — | 2 |
Pneumonia | D011014 | EFO_0003106 | J18 | — | — | 1 | — | — | 1 |
Thinness | D013851 | — | R63.6 | — | — | 1 | — | — | 1 |
Respiratory insufficiency | D012131 | — | J96.9 | — | — | 1 | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Ulcerative colitis | D003093 | EFO_0000729 | K51 | — | 3 | — | — | — | 3 |
Asthma | D001249 | EFO_0000270 | J45 | — | 2 | — | — | — | 2 |
Infections | D007239 | EFO_0000544 | — | — | 1 | — | — | — | 1 |
Chronic obstructive pulmonary disease | D029424 | EFO_0000341 | J44.9 | — | 1 | — | — | — | 1 |
Multiple organ failure | D009102 | EFO_1001373 | — | — | 1 | — | — | — | 1 |
Respiratory tract infections | D012141 | — | J06.9 | — | 1 | — | — | — | 1 |
Alzheimer disease | D000544 | EFO_0000249 | F03 | — | 1 | — | — | — | 1 |
Dementia | D003704 | EFO_0003862 | F03 | — | 1 | — | — | — | 1 |
Crohn disease | D003424 | EFO_0000384 | K50 | — | 1 | — | — | — | 1 |
Disease progression | D018450 | — | — | — | 1 | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Healthy volunteers/patients | — | — | — | 10 | — | — | — | — | 10 |
Pharmacokinetics | D010599 | — | — | 1 | — | — | — | — | 1 |
Pharmacological phenomena | D000069437 | — | — | 1 | — | — | — | — | 1 |
Therapeutic equivalency | D013810 | — | — | 1 | — | — | — | — | 1 |
Respiratory aspiration | D053120 | EFO_1001839 | — | 1 | — | — | — | — | 1 |
Renal insufficiency | D051437 | — | N19 | 1 | — | — | — | — | 1 |
Stroke | D020521 | EFO_0000712 | I63.9 | 1 | — | — | — | — | 1 |
Ischemia | D007511 | EFO_0000556 | — | 1 | — | — | — | — | 1 |
Inflammation | D007249 | MP_0001845 | — | 1 | — | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Acute kidney injury | D058186 | — | N17 | — | — | — | — | 1 | 1 |
Iatrogenic disease | D007049 | — | — | — | — | — | — | 1 | 1 |
Chronic progressive multiple sclerosis | D020528 | EFO_0003840 | — | — | — | — | — | 1 | 1 |
Atrophy | D001284 | — | — | — | — | — | — | 1 | 1 |
Patient satisfaction | D017060 | — | — | — | — | — | — | 1 | 1 |
Motor activity | D009043 | EFO_0003940 | — | — | — | — | — | 1 | 1 |
Exercise | D015444 | EFO_0000483 | — | — | — | — | — | 1 | 1 |
Medication adherence | D055118 | EFO_0006344 | — | — | — | — | — | 1 | 1 |
Metabolic bone diseases | D001851 | — | — | — | — | — | — | 1 | 1 |
Driving under the influence | D000066448 | — | — | — | — | — | — | 1 | 1 |
Drug common name | Interferon beta-1a |
INN | — |
Description | Interferon beta precursor (IFN-beta) (Fibroblast interferon) |
Classification | Protein |
Drug class | — |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | — |
PDB | — |
CAS-ID | — |
RxCUI | — |
ChEMBL ID | CHEMBL1201562 |
ChEBI ID | — |
PubChem CID | — |
DrugBank | DB00060 |
UNII ID | — |